1. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Issue 14 (6th December 2019) Authors: Foltz, Lynda; Pica, Gian-Matteo; Zerazhi, Hacene; Van Droogenbroeck, Jan; Visanica, Sorin; Báez de la Fuente, Enrique; Leber, Brian; de Almeida, Antonio Medina; Ranta, Dana; Kiladjian, Jean-Jacques; Chrit, Linda; Kandra, Albert; Morando, Juliane; Devos, Timothy Journal: Leukemia & lymphoma Issue: Volume 60:Issue 14(2019) Page Start: 3493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Issue 11 (10th April 2021) Authors: Oberic, Lucie; Peyrade, Frederic; Puyade, Mathieu; Bonnet, Christophe; Dartigues-Cuillères, Peggy; Fabiani, Bettina; Ruminy, Philippe; Maisonneuve, Hervé; Abraham, Julie; Thieblemont, Catherine; Feugier, Pierre; Salles, Gilles; Bijou, Fontanet; Pica, Gian-Matteo; Damaj, Gandhi; Haioun, Corinne; C... Journal: Journal of clinical oncology Issue: Volume 39:Issue 11(2021) Page Start: 1203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗